Carnosine vs Survodutide
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & LongevityRecovery & Repair
CarnosineGLP-1 / Weight Loss Agonists
Survodutide- Summary
- Carnosine is an endogenous dipeptide (beta-alanine + histidine) found in high concentrations in muscle and brain. It is a potent anti-aging molecule with broad spectrum antioxidant, anti-glycation, anti-carbonylation, and metal chelating properties, making it one of the most protective naturally occurring dipeptides.
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Half-Life
- ~1.5 minutes (rapidly hydrolyzed to beta-alanine and histidine by carnosinase in blood; tissue levels maintained via constant synthesis)
- ~7 days
- Admin Route
- Oral, Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 1,000–2,000 mg
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- Once to twice daily with meals
- Once weekly
- Key Benefits
- Potent anti-glycation (prevents protein cross-linking/aging)
- Broad-spectrum antioxidant in muscle and brain
- Extends cell lifespan and protects telomeres
- Improves muscle performance and delays fatigue (pH buffering)
- Neuroprotective against Alzheimer's amyloid-beta
- Wound healing acceleration
- Anti-cataract properties (eye health)
- Improves diabetes complications via AGE prevention
- Chelates excess copper and zinc
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Side Effects
- Very well tolerated
- Rare: mild GI discomfort at high doses
- No significant adverse effects in human studies
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Stacks With
- —
- —